The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago

Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Managing Editor
Table of Contents

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
Jacquelyn Cobb
Managing Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login